A Phase 2 interventional study of LT3001 Drug Product and Placebo in Acute Ischemic Stroke, sponsored by Lumosa Therapeutics Co., Ltd.. Completed at 10 sites in 2 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by Lumosa Therapeutics Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Ischemic Stroke with a site in Taiwan — 18 open to participants now, 21 under way, 3 of them phase 3. Ischemic Stroke · Taiwan.
Among the 64 studies in Ischemic Stroke with a site in Taiwan, this one is the 42nd largest by enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2020, is one of 9 in phase 2, and was the 27th registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →18 of the 64 studies in Ischemic Stroke with a site in Taiwan are open now. Recruiting first, the newest first:
Lumosa Therapeutics Co., Ltd. · Sites in Taiwan
Ages 18–88
En Chu Kong Hospital · Sites in Taiwan
Ages 20+
Boehringer Ingelheim · Sites in Taiwan, Argentina, Australia and 13 more countries
Ages 18+
Taichung Veterans General Hospital · Sites in Taiwan
Ages 18–90
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 13 · Phase 3 10 · Phase 4 1
First in 2005; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.
Median enrollment 73 across the 52 interventional studies, 200 across the 12 observational. Of the 30 that completed or were terminated, 7 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 64 have an industry lead sponsor. The 10 most frequent:
Lumosa Therapeutics Co., Ltd. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Lumosa Therapeutics Co., Ltd. has 5 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
4 of the studies in Ischemic Stroke with a site in Taiwan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07361302Phase 3Boehringer IngelheimA Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well | 2027-10-02 |
| NCT05198323Lumosa Therapeutics Co., Ltd.A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT | 2026-12-31 |
| NCT07784751Taipei Hospital, Ministry of Health and WelfareSafety, Dose-Finding, and Efficacy of Transcranial Pulse Stimulation for Post-Stroke Neurorehabilitation | 2027-08-24 |
| NCT07900503En Chu Kong HospitalSafety and Feasibility of NRICM301 Added to Usual Care for Adults With Acute Ischemic Stroke | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 64 studies in Ischemic Stroke with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, double-blind, single-dose, randomized, and placebo-controlled prospective Phase IIa clinical study, designed to evaluate LT3001 drug product versus placebo/control in subjects with AIS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: LT3001 Drug Product
Drug: Placebo
Active comparator
Placebo comparator
The Percentage of Subject Have Symptomatic Intracranial Hemorrhage (sICH) of a Single Dose LT3001 Drug Product in Subjects With AIS.
Compare the the percentage of subject having sICH between LT3001 drug product and Placebo.
Time frame: Within 36 hours
| Milestone | LT3001 Drug Product | Placebo |
|---|---|---|
| Started | 16 | 8 |
| Completed | 14 | 7 |
| Not completed | 2 | 1 |
Compare the the percentage of subject having sICH between LT3001 drug product and Placebo.
| Participants | LT3001 Drug Product | Placebo |
|---|---|---|
| The Percentage of Subject Have Symptomatic Intracranial Hemorrhage (sICH) of a Single Dose LT3001 Drug Product in Subjects With AIS. | 0 | 0 |
Collected over From the time the subject received the IP until the last follow-up visit, approximately 92 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LT3001 Drug Product | 1/16 (6.3%) | 4/16 (25%) | 16/16 (100%) |
| Placebo | 1/8 (12.5%) | 2/8 (25%) | 7/8 (87.5%) |
| Event | LT3001 Drug Product | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 1/16 | 1/8 |
| COVID-19Infections and infestations | 0/16 | 1/8 |
| Staphylococcal infectionInfections and infestations | 0/16 | 1/8 |
| Stroke in evolutionNervous system disorders | 2/16 | 0/8 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 1/16 | 1/8 |
| Respiratory arrestRespiratory, thoracic and mediastinal disorders | 0/16 | 1/8 |
| Cerebral infarctionNervous system disorders | 1/16 | 0/8 |
| Bronchial neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/16 | 0/8 |
| Event | LT3001 Drug Product | Placebo |
|---|---|---|
| ConstipationGastrointestinal disorders | 10/16 | 4/8 |
| HeadacheNervous system disorders | 2/16 | 2/8 |
| HypertensionVascular disorders | 2/16 | 2/8 |
| PneumoniaInfections and infestations | 2/16 | 2/8 |
| C-reactive protein increasedInvestigations | 1/16 | 2/8 |
| DiarrhoeaGastrointestinal disorders | 3/16 | 2/8 |
| HyponatraemiaMetabolism and nutrition disorders | 1/16 | 2/8 |
| AtelectasisRespiratory, thoracic and mediastinal disorders | 0/16 | 2/8 |
| NephrolithiasisRenal and urinary disorders | 0/16 | 2/8 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/16 | 0/8 |
| Age, Continuous(years) | LT3001 Drug Product | Placebo | Total |
|---|---|---|---|
| Mean | 62.1 ± 12.63 | 67.6 ± 9.24 | 63.9 ± 11.71 |
| Sex: Female, Male(Participants) | LT3001 Drug Product | Placebo | Total |
|---|---|---|---|
| Female | 4 | 1 | 5 |
| Male | 12 | 7 | 19 |
| Ethnicity (NIH/OMB)(Participants) | LT3001 Drug Product | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 15 | 3 | 18 |
| Unknown or Not Reported | 1 | 5 | 6 |
| Race (NIH/OMB)(Participants) | LT3001 Drug Product | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 15 | 3 | 18 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 1 | 5 | 6 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2020 to primary completion in Feb 2021, 12 months.
Results were first posted in Dec 2025, 4 years 10 months after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's 12 months is below that.
Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LT3001
Lumosa Therapeutics Co., Ltd.